Description

The global lysosomal storage disease treatment market size is projected to grow from USD 7.57 billion in 2020 to USD 13.41 billion in 2027, at a 10.2% CAGR during the forecast period, 2021-2027. Lysosomal storage diseases (LSD) belong to a group of inherited metabolic diseases that may occur from the deficit of the production of lysosomal enzymes. There are nearly 50 types of lysosomal storage diseases found in different human body parts, such as the skull, brain, heart, body, skin, and others. Gaucher disease, pompe disease, Fabry disease are some of the critical lysosomal storage diseases.  However, there are limited medication facilities for lysosomal storage diseases recently, and the treatment is mostly symptomatic.

Factors Affecting the Lysosomal Storage Disease Treatment Industry over the Forecast Period:

Increasing research and development (R&D) for the diagnosis & treatment and rising financial incentives for drug development will raise the demand for lysosomal storage disease treatment, increasing the global market. Factors such as a rise in diagnostic rate, increase in the incidence of lysosomal storage diseases, and implementation of the orphan drug are anticipated to drive the global growth for the lysosomal storage disease treatment market.

Growing awareness among people regarding rare lysosomal storage diseases also boosts the growth of the lysosomal storage disease treatment market in the healthcare and pharmaceutical sector across the globe significantly.

However, underdiagnosed lysosomal storage disease due to the lack of heterogeneity of the lysosomal disorder, high cost of treatment, and lack of treatment options may restrain the growth of lysosomal storage disease treatment in the global market over the forecast period.

Impact of COVID-19 on Lysosomal Storage Disease Treatment Market:

COVID-19 is a global public health disease that has affected almost every industry. The outbreak of COVID-19 has led to a significant decline in the demand for the lysosomal storage disease treatment market across several sectors, primarily the health and pharmaceutical sector, as coronavirus crises take over the world and led to healthcare organizations dedicating the majority of their funds towards resources required to battle COVID-19. Additionally, patients receiving lysosomal storage disease treatment in hospitals experience disruptions, and the main reason for this was the threat of infection. Therefore, with the outbreak of the COVID-19, the market will grow at a low rate for lysosomal storage disease treatment across the globe, which has negatively impacted the lysosomal storage disease treatment market value in 2020 and subsequent years.

Scope of the Report

The report outlines the lysosomal storage disease treatment market study based on type, therapy, and end-users.

Based on the disease type, the lysosomal storage disease treatment market has been segmented into –

• Batten Disease
• Cystinosis
• Fabry Disease
• Gaucher disease
• Others

Based on the therapy, the lysosomal storage disease treatment market has been segmented into –

• Enzyme Replacement Therapy
• Stem Cell Transplantation
• Substrate Reduction Therapy
• Others

Based on the end-users, the lysosomal storage disease treatment market has been segmented into –

• Hospitals
• Clinics
• Research Organizations
• Others

Lysosomal Storage Disease Treatment Market: Regional Outlook

Based on the region, the global lysosomal storage disease treatment market has been segmented into five geographical regions, namely, North America, Asia Pacific, Europe, South America, and the Middle East and Africa. In 2020, North America held the largest share in the market size in the lysosomal storage disease treatment market, followed by Europe and Asia-Pacific, due to the increasing prevalence and incidence of lysosomal storage diseases and growing R&D expenditure for the treatment of lysosomal storage disease in the region. Moreover, Asia Pacific is expected to grow at the highest CAGR globally over the forecast period, owing to the high prevalence of inherited abnormalities and disorders associated with lysosomal storage and booming healthcare infrastructure in the region.

Key Global Lysosomal Storage Disease Treatment Market Competitors Includes –

The lysosomal storage disease treatment market is highly fragmented, with a large number of small players across the globe. The vital lysosomal storage disease treatment manufacturers operating in the global market are –

• Pfizer, Inc.
• Sanofi (Genzyme Corporation)
• Eli Lilly and Company
• BioMarin Pharmaceutical Inc.
• Actelion Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Shire plc
• Protalix Biotherapeutics Inc.
• Amicus Therapeutics Inc.
• Raptor Pharmaceutical Corp.

The lysosomal storage disease treatment market report thoroughly analyzes macro-economic factors and every segment's market attractiveness. The report will include an in-depth qualitative and quantitative assessment of the segmental/regional outlook with the market players' presence in the respective segment and region/country. The information concluded in the report includes the inputs.

Lysosomal Storage Disease Treatment Market Report Covers Comprehensive Analysis On:

• Market Segmentation & Regional Analysis
• Market Size of 10 years
• Pricing Analysis
• Supply & Demand Analysis
• Product Life Cycle Analysis
• Porter's Five Forces & Value Chain Analysis
• Developed & Emerging Economies Analysis
• PEST Analysis
• Market and Forecast Factor Analysis
• Market Opportunities, Risks, & Trends
• Conclusion & Recommendation
• Regulatory Landscape
• Patent Analysis
• Competition Landscape
• 15+ Company Profiles

Lysosomal Storage Disease Treatment Market Regional Analysis Includes:

• North America (US, Canada, Mexico)
• South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
• Europe (Germany, Italy, France, UK, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, the Netherlands, Norway, Sweden, Denmark, Rest of Europe)
• Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, the Philippines, Singapore, Australia & New Zealand, Rest of Asia Pacific)
• The Middle East & Africa (Saudi Arabia, UAE, South Africa, Northern Africa, Rest of MEA

Lysosomal Storage Disease Treatment Market: Target Audience

• Lysosomal storage disease treatment manufacturers
• Investors and trade experts
• Healthcare manufacturers, distributors, and suppliers
• Trade publications and magazines
• Government authorities, associations, and organizations

Key Issues Addressed

• What is the market size by various segmentation of the lysosomal storage disease treatment by region and its respective countries?
• What are the customer buying behavior, key takeaways, and Porter's 5 forces of the lysosomal storage disease treatment market?
• What are the key opportunities and trends for manufacturers involved in the lysosomal storage disease treatment supply chain?
• What are the fundamental dynamics (drivers, restraints, opportunities, and challenges) of the market?
• What and how regulations, schemes, patents, and policies are impacting the growth of the market?
• What are the upcoming technological solutions influencing market trends? How will existing companies adapt to the new change in technology?
• What will be the impact of cutting-edge technology on the lysosomal storage disease treatment market?
• How has COVID-19 impacted the demand and sales of lysosomal storage disease treatment in the global market? Also, the expected BPS drop or rise count of the market and market expected recovery period.
• Detailed analysis of the competitors and their latest launch, and what are the prominent startups introduced in the target market? Also, detailed company profiling of 25+ leading and prominent companies in the market.